NCT02392455Completed
VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)
Vargatef in 2nd-line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung
Source: ClinicalTrials.gov · Last updated 28 Jul 2025
Brief summary (registry, in English)
This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC. Treatment with Vargatef in eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with Vargatef in second line according to the local label, will be observed for up to 24 months. Survial follow-up will be done until the end of the study.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 817 (actual)
- First submitted
- 17 Mar 2015
- Start date
- 23 Mar 2015
- Primary completion date
- 23 Jul 2025
- Lead sponsor
- Boehringer Ingelheim
- Diseases
- Lung cancer
- NCT number
- NCT02392455
What you commit to
- Study type: Observational
- Participants enrolled: 817
- From 23 Mar 2015 to the primary completion date, 23 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- more than one chemotherapy for treatment of NSCLC in palliative setting
Other
- contraindications according to the SmPC of Vargatef or Docetaxel
- current partcipation in a clinical trial
- pregnancy
- breastfeeding
Who the study is looking for
- age 18 or older
- men and women locally advanced, metastastic and/or recurrent NSCLC with adenocarcinoma histology for which vargatef treatment is indicated according to Summary of Product Characteristics (SmPC)
- after first line chemotherapy. This includes also combinations of immune- and chemotherapy.
- standard 21-day-cycles docetaxel treatment according to SmPC possible
- written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Multiple Locations | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.